International
Albania
Bosnia and Herzegovina
Bulgaria
Croatia
Czech Republic
Estonia
Hungary
Latvia
Lithuania
Kosovo
North Macedonia
Poland
Romania
Serbia
Slovakia
Slovenia
Switzerland (German)
Switzerland (French)
Business Development
Média
Recontrez nous
Carrière
Contact
Nos Produits
Partenaires & Marques
Témoignages
À propos d'Ewopharma
Vision/Mission
Nos valeurs
Notre stratégie
Leadership
Responsabilité sociale
Territoire
Business Development
Média
Recontrez nous
Carrière
Contact
International
Albania
Bosnia and Herzegovina
Bulgaria
Croatia
Czech Republic
Estonia
Hungary
Latvia
Lithuania
Kosovo
North Macedonia
Poland
Romania
Serbia
Slovakia
Slovenia
Switzerland (German)
Switzerland (French)
Média
COMMUNIQUÈS DE PRESSE
1
2
3
4
Suivant
31-07-2024
European Commission Approves Sugemalimab
Lire la suite
03-06-2024
AllergyCare AG devient membre du groupe Ewopharma
Lire la suite
27-05-2024
Ewopharma and CStone enter into a Strategic Partnership for Sugemalimab in Central Eastern Europe and Switzerland
Lire la suite
30-01-2024
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Lire la suite
31-05-2023
Neomed s.r.o. becomes part of Ewopharma Group
Lire la suite
1
2
3
4
Suivant
![[Translate to Switzerland (French):]](/fileadmin/user_upload/Licensing_450606453.jpg "[Translate to Switzerland (French):]")
